Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DVL1 | O14640 | 3/20 | 0.52 |
| ▸ | DVL3 | Q92997 | 3/20 | 0.52 |
| ▸ | BRS3 | P32247 | 3/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381538 | 1.00 | DVL1 (0.52) | DVL1DVL3BRS3RARBEGFR | |
| SCHEMBL10259840 | 0.89 | DVL1 (0.38) | DVL1DVL3EGFRCDK2GABRA1 | |
| SCHEMBL3078012 | 0.80 | DVL1 (0.60) | DVL1DVL3RARBEGFRCDK2 | |
| SCHEMBL4251120 | 0.73 | DVL1 (0.52) | DVL1DVL3RARBEGFRCDK2 | |
| SCHEMBL10291567 | 0.70 | DVL1 (0.48) | DVL1DVL3EGFRCDK2GABRA1 | |
| SCHEMBL4431001 | 0.67 | ADRB2 (0.47) | DVL1DVL3RARBADRB2CNR1 | |
| SCHEMBL6028909 | 0.66 | MLKL (0.36) | DVL1DVL3RARB | |
| SCHEMBL28006996 | 0.65 | RARB (0.39) | BRS3RARBPPARGPTGESALOX5 | |
| SCHEMBL28006956 | 0.65 | RARB (0.59) | RARB | |
| SCHEMBL21303574 | 0.65 | RARB (0.36) | BRS3RARBPPARGPTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285498-A1 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE | 2023-09-14 | — | — | US | disclosed |
| US-20140255426-A1 | WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-8211934-B2 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211934-B2 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211934-B2 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110160263-A1 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-06-30 | — | — | US | disclosed |
| US-20110160263-A1 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-06-30 | — | — | US | disclosed |
| US-20110160263-A1 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-06-30 | — | — | US | disclosed |
| US-7795295-B2 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795295-B2 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795295-B2 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080064733-A1 | Small Molecule Inhibition of Pdz-Domain Interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-03-13 | — | — | US | disclosed |
| US-20080064733-A1 | Small Molecule Inhibition of Pdz-Domain Interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-03-13 | — | — | US | disclosed |
| US-20080064733-A1 | Small Molecule Inhibition of Pdz-Domain Interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064733-A1 | Small Molecule Inhibition of Pdz-Domain Interaction | DVL1, DVL3, PDLIM5 | DVL1 1/4885DVL3 2/4885BRS3 3914/4885 |
| US-20110160263-A1 | Small molecule inhibition of PDZ-domain interaction | DVL1, DVL3, PDLIM5 | DVL1 1/4885DVL3 2/4885BRS3 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.